Novo Nordisk rebounds
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...
Get key updates on stock ratings this week, from Intel's leadership-driven upgrade to Apple's tariff challenges.
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...
Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback